Leerink Partnrs Has Positive Outlook of Immunic Q2 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.16) for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.55) EPS.

Several other analysts have also weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $17.00 target price on shares of Immunic in a research report on Wednesday, April 30th. B. Riley reiterated a “buy” rating and issued a $6.00 price objective on shares of Immunic in a research note on Wednesday, April 16th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday. William Blair began coverage on Immunic in a research report on Tuesday, March 25th. They issued an “outperform” rating on the stock. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic has a consensus rating of “Buy” and a consensus target price of $13.20.

Immunic Price Performance

IMUX opened at $1.15 on Monday. The company has a market capitalization of $110.19 million, a P/E ratio of -0.93 and a beta of 1.73. The firm’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.11. Immunic has a fifty-two week low of $0.83 and a fifty-two week high of $2.11.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently modified their holdings of the stock. Focus Partners Wealth increased its holdings in shares of Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares in the last quarter. 683 Capital Management LLC increased its stake in shares of Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares during the period. Millennium Management LLC raised its position in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after acquiring an additional 479,846 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after acquiring an additional 177,542 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the period. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.